Antibody drug conjugates

Patent metadata

Field	Value
Publication number	US-10626172-B2
Application number	US-201815988659-A
Country	US
Kind code	B2
Filing date	May 24, 2018
Priority date	Nov 14, 2014
Publication date	Apr 21, 2020
Grant date	Apr 21, 2020

Abstract

This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

First claim

We claim:

1. A nucleic acid that encodes an antibody or antigen binding fragment thereof comprising:
a. a heavy chain variable region that comprises a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, and a VH CDR3 of SEQ ID NO: 3, wherein the CDR is defined in accordance with the Kabat definition; and a light chain variable region that comprises a VL CDR1 of SEQ ID NO: 11, a VL CDR2 of SEQ ID NO: 12, and a VL CDR3 of SEQ ID NO: 13, wherein the CDR is defined in accordance with the Kabat definition;
b. a heavy chain variable region that comprises a VH CDR1 of SEQ ID NO: 21, a VH CDR2 of SEQ ID NO: 22, and a VH CDR3 of SEQ ID NO: 23, wherein the CDR is defined in accordance with the Kabat definition; and a light chain variable region that comprises a VL CDR1 of SEQ ID NO: 31, a VL CDR2 of SEQ ID NO: 32, and a VL CDR3 of SEQ ID NO: 33, wherein the CDR is defined in accordance with the Kabat definition;
c. a heavy chain variable region that comprises a VH CDR1 of SEQ ID NO:41, a VH CDR2 of SEQ ID NO:42, and a VH CDR3 of SEQ ID NO:43, wherein the CDR is defined in accordance with the Kabat definition; and a light chain variable region that comprises a VL CDR1 of SEQ ID NO:51, a VL CDR2 of SEQ ID NO:52, and a VL CDR3 of SEQ ID NO:53, wherein the CDR is defined in accordance with the Kabat definition;
d. a heavy chain variable region that comprises a VH CDR1 of SEQ ID NO:61, a VH CDR2 of SEQ ID NO:62, and a VH CDR3 of SEQ ID NO:63, wherein the CDR is defined in accordance with the Kabat definition; and a light chain variable region that comprises a VL CDR1 of SEQ ID NO:71, a VL CDR2 of SEQ ID NO:72, and a VL CDR3 of SEQ ID NO:73, wherein the CDR is defined in accordance with the Kabat definition;
e. a heavy chain variable region that comprises a VH CDR1 of SEQ ID NO:81, a VH CDR2 of SEQ ID NO:82, and a VH CDR3 of SEQ ID NO:83, wherein the CDR is defined in accordance with the Kabat definition; and a light chain variable region that comprises a VL CDR1 of SEQ ID NO:91, a VL CDR2 of SEQ ID NO:92, and a VL CDR3 of SEQ ID NO:93, wherein the CDR is defined in accordance with the Kabat definition; or
f. a heavy chain variable region that comprises a VH CDR1 of SEQ ID NO:101, a VH CDR2 of SEQ ID NO:102, and a VH CDR3 of SEQ ID NO:103, wherein the CDR is defined in accordance with the Kabat definition; and a light chain variable region that comprises a VL CDR1 of SEQ ID NO:111, a VL CDR2 of SEQ ID NO:112, and a VL CDR3 of SEQ ID NO:113, wherein the CDR is defined in accordance with the Kabat definition.

2. The nucleic acid of claim 1 , wherein the nucleic acid comprises the nucleotide sequence of SEQ ID NOs: 8, 28, 48, 68, 88, 108, 18, 38, 58, 78, 98, 118, 10, 30, 50, 70, 90, 110, 20, 40, 60, 80, 100, and 120.

3. A vector comprising the nucleic acid of claim 1 .

4. A host cell comprising the vector or the nucleic acid according to claim 1 .

5. A process for producing an antibody or antigen binding fragment comprising cultivating the host cell of claim 4 and recovering the antibody from the culture.

Assignees

• Abrams Tinya
• Cohen Steven Bruce
• Damiano Jason
• Duerr Clemens
• Huber Thomas
• Menezes Daniel
• Miller Kathy
• Rendahl Katherine
• Rondeau Jean Michel Rene
• Novartis Ag

Inventors

• Abrams Tinya
• Cohen Steven Bruce
• Damiano Jason
• Dürr Clemens
• Huber Thomas
• Menezes Daniel
• Miller Kathy
• Rendahl Katherine
• Rondeau Jean-Michel Rene

Classifications

• A61K47/6851

  the antibody targeting a determinant of a tumour cell · CPC title

• C07K2317/51

  Complete heavy chain or Fd fragment, i.e. VH + CH1 · CPC title

• C07K2317/55

  Fab or Fab' · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K16/28 Primary

  against receptors, cell surface antigens or cell surface determinants · CPC title